(abiraterone acetate + niraparib)
Marketedupdated 2mo agoby $JNJ JOHNSON & JOHNSON
Approvedcommunity read0 votes
all catalysts(2)
News(0)
no news has mentioned this drug yet
no news has mentioned this drug yet
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
comments(0)
5-min edit window · permanent after that